Israel Englander’s United Therapeutics UTHR Stock Holding History

Israel Englander’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.46M	Sell	2,700 -76,200	-97%	-$42.9M	﹤0.01%	4070
2026 Q1	$46.8M	Buy	+78,900	New	+$39.3M	0.02%	868
2025 Q4	–	Sell	-12,100	Closed	-$5.07M	–	6484
2025 Q3	$5.07M	Buy	+12,100	New	+$4.07M	﹤0.01%	3136
2025 Q1	–	Sell	-3,300	Closed	-$1.16M	–	6421
2024 Q4	$1.16M	Sell	3,300 -7,100	-68%	-$2.61M	﹤0.01%	4076
2024 Q3	$3.73M	Sell	10,400 -2,300	-18%	-$777K	﹤0.01%	3105
2024 Q2	$4.05M	Buy	+12,700	New	+$3.36M	﹤0.01%	2908
2021 Q2	–	Sell	-50,000	Closed	-$8.36M	–	7138
2021 Q1	$8.36M	Buy	+50,000	New	+$8.34M	0.01%	1987
2019 Q4	–	Sell	-10,000	Closed	-$797K	–	4660
2019 Q3	$797K	Buy	+10,000	New	+$805K	﹤0.01%	2979
2017 Q4	–	Sell	-7,500	Closed	-$879K	–	4096
2017 Q3	$879K	Buy	+7,500	New	+$958K	﹤0.01%	2584
2017 Q2	–	Sell	-15,000	Closed	-$2.03M	–	3889
2017 Q1	$2.03M	Buy	+15,000	New	+$2.27M	﹤0.01%	2005
2015 Q2	–	Sell	-1,500	Closed	-$259K	–	3873
2015 Q1	$259K	Buy	+1,500	New	+$229K	﹤0.01%	3137

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Norges Bank Oslo, Norway $1T AUM

Israel Englander's UTHR Position: Q2 2026 in Review

Israel Englander increased its United Therapeutics (UTHR) stake by 167% in Q2 2026, buying an estimated $144M and bringing the position to 409,074 shares worth $222M. The position accounts for 0.08% of the portfolio, ranked #208.

Israel Englander first reported a position in UTHR in Q2 2013 and has held it in 51 quarters since. 874 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

Israel Englander held 409,074 shares of United Therapeutics worth $222M as of Q2 2026.
Israel Englander bought 255,702 United Therapeutics shares in Q2 2026, an estimated $144M.
United Therapeutics made up 0.08% of Israel Englander's portfolio in Q2 2026, its #208 holding.
Israel Englander first reported a position in United Therapeutics in Q2 2013 and has held it in 51 quarters since.
874 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.